Ημερομηνία: 18/12/2020
PC Statement On SARS-CoV-2 Vaccines And Psoriasis
Newswise — ST. LOUIS, Dec. 2, 2020 /PRNewswire/ — The SARS-CoV-2 pandemic
continues to have a considerable impact on the provision of appropriate
care to people with psoriasis. In many countries there is currently great
excitement about the potential initiation of vaccination programs to people
at risk and the general population. While this news is to be welcomed, the
impact of psoriasis therapy, particularly systemic therapy, on the
effectiveness and safety of vaccines needs to be considered.
The International Psoriasis Council (IPC) advises physicians and other
healthcare practitioners to take into account the following:
-
The principal considerations for SARS-CoV-2 vaccines are the same
as for any vaccine:
Avoid live-attenuated vaccines if receiving an
immunosuppressive/immunomodulatory medication and be aware that the
effectiveness of vaccination may be attenuated in people taking drugs
that affect the immune system. -
Currently the three vaccines closest to use at a population level
are either RNA-based (Pfizer/BioNTech, Moderna) or based on
replication deficient virus (Oxford/AstraZeneca
). Thus, they are not live attenuated vaccines. -
We anticipate that most patients with psoriasis who do not have a
contraindication or a known allergy to a vaccine component will be
recommended to receive one of these SARS-CoV-2 vaccines as soon as
possible based on local availability and guidance from local public
health bodies. -
Trials to date have not included people taking drugs that affect the
immune system and thus the effects of the vaccines in this specific
population will need to be established. -
Many people with psoriasis have raised concerns about potential adverse
effects of vaccines on their skin disease. However, there is no
evidence that vaccines affect psoriasis onset or severity.
Registry data should be collected to inform whether SARS-Cov-2
vaccines either positively or negatively affect psoriasis outcomes
. -
It is important that all people with psoriasis have access to adequate
care. This includes access to SARS-CoV-2 vaccines.
The IPC will continue to provide updates to the global dermatology
community as we learn more about SARS-CoV-2, vaccines and their impact on
psoriasis.
For the latest information on the coronavirus (COVID-19) outbreak,
including
prevention
and
signs and symptoms
of the disease, refer to the
World Health Organization (WHO)
website.
About International Psoriasis Council
The
International Psoriasis Council
is a dermatologist-led global organization with a network of more than 100
psoriasis experts dedicated to improving the health of people with
psoriasis. IPC helps psoriasis patients get better care and treatment by
conducting research into the disease and providing health care
professionals with resources and education to best manage their patients
with psoriasis.
**** Κατεβάστε εδώ το έγγραφο ****
Εκ Μέρους της Ελληνικής Δερματολογικής & Αφροδισιολογικής Εταιρείας.
www.edae.gr